Indoco Remedies Reports Q4 FY26 Results; Turnaround in Profitability and Dividend Declaration

Synopsis: Indoco Remedies Limited reported a strong recovery in its Q4 FY26 results, posting a net profit of Rs. 27.35 crore compared to a loss in the previous year. The Board recommended a 10% dividend and highlighted significant growth in international markets despite an exceptional expense related to new Indian Labour Codes.

In a Board meeting held on May 7, 2026, Indoco Remedies Limited approved its audited financial results for the quarter and year ended March 31, 2026. The company achieved a total income of Rs. 459.48 crore for the quarter, marking a substantial increase from Rs. 353.75 crore in Q4 FY25.

A key highlight was the turnaround in profitability; the company reported a net profit of Rs. 27.35 crore for Q4 FY26, rebounding from a net loss of Rs. 26.24 crore in the same period last year. For the full financial year 2025-26, the company recommended a dividend of Rs. 0.20 per equity share (10% on a face value of Rs. 2/-).

On a standalone basis, the company reported total income of Rs. 1,715.71 crore in FY26, compared with Rs. 1,536.67 crore in FY25. Despite the strong quarterly performance, Indoco’s standalone operations ended the financial year with a net loss of Rs. 5.66 crore, an improvement from the Rs. 8.73 crore loss recorded in the previous year. However, on a consolidated basis, the group reported a wider net loss of Rs. 98.70 crore for the full year

The results were influenced by an exceptional item of Rs. 2.86 crore. This included a one-time liability of Rs. 4.19 crore due to the implementation of the New Labour Codes (Code on Wages, Industrial Relations, Social Security, and Occupational Safety), which required higher provisions for gratuity and leave liabilities.

The market responded strongly to the earnings turnaround. As of 1:26 PM IST on May 7, 2026, Indoco Remedies’ stock was trading at Rs. 260.00 on the NSE, marking a sharp gain of 13.72% from its previous close. During the trading session, the stock touched an intraday high of Rs. 270.00, with around 11.13 lakh shares changing hands. The company currently commands a market capitalization of Rs. 2,397.22 crore.

The rally reflects improving investor confidence after the company reported a notable recovery in its international business segment. International revenue rose significantly to Rs. 235.43 crore in the quarter, compared with Rs. 124.68 crore in the same period last year, signalling a strong rebound in overseas operations.

Indoco Remedies Limited is a fully integrated, research-oriented pharmaceutical company with a turnover of approximately US$ 175 million. The company employs over 6,000 people and operates 10 manufacturing facilities (6 for Finished Dosage Forms and 4 for APIs) approved by major global regulators including the USFDA and UK-MHRA. Indoco holds a strong brand portfolio in therapeutic segments such as Gastro-intestinal, Respiratory, and Stomatologicals, with top brands including Cyclopam, Febrex Plus, and Sensodent-K.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Indoco Remedies Reports Q4 FY26 Results; Turnaround in Profitability and Dividend Declaration appeared first on Trade Brains.